Effect of the blockade of the IL-23-Th17-IL-17A pathway on streptozotocin-induced diabetic retinopathy in rats

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 253, Issue 9, 2015, Pages 1485-1492

  Xu, Haiyan ^a,b   Cai, Min ^a,b   Zhang, Xuedong ^a,b  

^a THE FIRST AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^b Chongqing Eye Institute   (China)

Author keywords

Anti IL 23Rp19 antibody; Blood retinal barrier; STZ induced retinopathy; Th17 cells

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 23 ANTIBODY; INTERLEUKIN 23RP19 ANTIBODY; MESSENGER RNA; STREPTOZOCIN; UNCLASSIFIED DRUG; IL17 PROTEIN, RAT; INTERLEUKIN 23P19;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TH17 CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CAPILLARY PERMEABILITY; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE COURSE; GENETICS; METABOLISM; PHYSIOLOGY; RAT; RETINA BLOOD VESSEL; SPRAGUE DAWLEY RAT;

ANIMALS; BLOOD-RETINAL BARRIER; CAPILLARY PERMEABILITY; CD4-POSITIVE T-LYMPHOCYTES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DIABETIC RETINOPATHY; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKIN-23 SUBUNIT P19; MALE; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RETINAL VESSELS; RNA, MESSENGER; TH17 CELLS;

EID: 84940437043     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-014-2842-9     Document Type: Article

References (32)

1. Ola MS, Nawaz MI, Siddiquei MM et al (2012) Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy. J Diabetes Complicat 26:56–64. doi:10.1016/j.jdiacomp.2011.11.004
2. Yau JW, Rogers SL, Kawasaki R et al (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35:556–564. doi:10.2337/dc11-1909
3. Cheung CMG, Vania M, Ang M et al (2012) Comparison of aqueous humor cytokine and chemokine levels in diabetic patients with and without retinopathy. Mol Vis 18:830–837
4. Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107:1058–1070. doi:10.1161/circresaha.110.223545
5. Milne R, Brownstein S (2013) Advanced glycation end products and diabetic retinopathy. Amino Acids 44:1397–1407. doi:10.1007/s00726-011-1071-3
6. Tomic M, Ljubic S, Kastelan S (2013) The role of inflammation and endothelial dysfunction in the pathogenesis of diabetic retinopathy. Coll Antropol 37(Suppl 1):51–57
7. Zipris D (2008) Innate immunity and its role in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 15:326–331. doi:10.1097/MED.0b013e3283073a46
8. Shao S, He F, Yang Y et al (2012) Th17 cells in type 1 diabetes. Cell Immunol 280:16–21. doi:10.1016/j.cellimm.2012.11.001
9. Maddur MS, Miossec P, Kaveri SV et al (2012) Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies. Am J Pathol 181:8–18. doi:10.1016/j.ajpath.2012.03.044
10. Park H, Li Z, Yang XO et al (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6:1133–1141. doi:10.1038/ni1261
11. Nadeem A, Javaid K, Sami W et al (2013) Inverse relationship of serum IL-17 with type-II diabetes retinopathy. Clin Lab 59:1311–1317
12. Chen Y, Yang P, Li F et al (2011) The effects of Th17 cytokines on the inflammatory mediator production and barrier function of ARPE-19 cells. PLoS One 6:e18139. doi:10.1371/journal.pone.0018139
13. Ryba-Stanislawowska M, Skrzypkowska M, Mysliwiec M et al (2013) Loss of the balance between CD4(+)Foxp3(+) regulatory T cells and CD4(+)IL17A(+) Th17 cells in patients with type 1 diabetes. Hum Immunol 74:701–707. doi:10.1016/j.humimm.2013.01.024
14. Zuniga LA, Jain R, Haines C et al (2013) Th17 cell development: from the cradle to the grave. Immunol Rev 252:78–88. doi:10.1111/imr.12036
15. Basso AS, Cheroutre H, Mucida D (2009) More stories on Th17 cells. Cell Res 19:399–411. doi:10.1038/cr.2009.26
16. Bi Y, Yang R (2012) Direct and indirect regulatory mechanisms in TH17 cell differentiation and functions. Scand J Immunol 75:543–552. doi:10.1111/j.1365-3083.2012.02686.x
17. Yang XO, Pappu BP, Nurieva R et al (2008) T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 28:29–39. doi:10.1016/j.immuni.2007.11.016
18. Lee Y, Awasthi A, Yosef N et al (2012) Induction and molecular signature of pathogenic TH17 cells. Nat Immunol 13:991–999. doi:10.1038/ni.2416
19. Niimi N, Kohyama K, Matsumoto Y (2013) Therapeutic gene silencing with siRNA for IL-23 but not for IL-17 suppresses the development of experimental autoimmune encephalomyelitis in rats. J Neuroimmunol 254:39–45. doi:10.1016/j.jneuroim.2012.08.015
20. Toussirot E (2012) The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets 11:159–168
21. Honkanen J, Nieminen JK, Gao R et al (2010) IL-17 immunity in human type 1 diabetes. J Immunol 185:1959–1967. doi:10.4049/jimmunol.1000788
22. Iwakura Y, Nakae S, Saijo S et al (2008) The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 226:57–79. doi:10.1111/j.1600-065X.2008.00699.x
23. Runkle EA, Antonetti DA (2011) The blood-retinal barrier: structure and functional significance. Methods Mol Biol 686:133–148. doi:10.1007/978-1-60761-938-3_5
24. Kaya A, Kar T, Aksoy Y et al (2013) Insulin analogues may accelerate progression of diabetic retinopathy after impairment of inner blood-retinal barrier. Med Hypotheses 81:1012–1014. doi:10.1016/j.mehy.2013.09.018
25. Chen HT, Wang H, Zhao M et al (2012) Regulation of antigen specific Th17 cells differentiation in experimental autoimmune uveitis. Zhonghua Yan Ke Za Zhi 48:234–240
26. Brandon JA, Jennings CD, Kaplan AM et al (2013) Anti-IL-23p19 therapy inhibits the adoptive transfer of syngeneic graft-versus-host disease. Cytokine 61:732–735. doi:10.1016/j.cyto.2013.01.005
27. Wu SY, Yu JS, Liu FT et al (2013) Galectin-3 negatively regulates dendritic cell production of IL-23/IL-17-axis cytokines in infection by Histoplasma capsulatum. J Immunol 190:3427–3437. doi:10.4049/jimmunol.1202122
28. Sato K (2013) The IL-23/IL-17 axis as a therapeutic target. Nihon Rinsho Men’eki Gakkai Kaishi Jpn J Clin Immunol 36:203–208
29. Kwok SK, Cho ML, Her YM et al (2012) TLR2 ligation induces the production of IL-23/IL-17 via IL-6, STAT3 and NF-kB pathway in patients with primary Sjogren’s syndrome. Arthritis Res Ther 14:R64. doi:10.1186/ar3780
30. Korn T, Bettelli E, Oukka M et al (2009) IL-17 and Th17 cells. Annu Rev Immunol 27:485–517. doi:10.1146/annurev.immunol.021908.132710
31. Kim HR, Kim HS, Park MK et al (2007) The clinical role of IL-23p19 in patients with rheumatoid arthritis. Scand J Rheumatol 36:259–264. doi:10.1080/03009740701286813
32. Ratsimandresy RA, Duvallet E, Assier E et al (2011) Active immunization against IL-23p19 improves experimental arthritis. Vaccine 29:9329–9336. doi:10.1016/j.vaccine.2011.09.134